A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
for Unresectable Head and Neck Squamous Cell Carcinoma
19 locations incl. Los Angeles
Sponsor: BioNTech SE
Sex: All·Age: 18+
Code: NCT04534205·Phase 2, Phase 3·Recruiting